Attacking drug-resistant tumors with Sierra's struggling CHK1 blocker

Sierra Oncology deprioritized the development of its CHK1 blocker SRA737 last year, as it steered most of its dwindling resources towards developing a phase 3 myelofibrosis drug that it picked up from Gilead. Now British scientists say SRA737 has the potential to treat several tumor types as part of a combination with another protein blocker.

Attacking drug-resistant tumors with Sierra's struggling CHK1 blocker
Sierra Oncology deprioritized the development of its CHK1 blocker SRA737 last year, as it steered most of its dwindling resources towards developing a phase 3 myelofibrosis drug that it picked up from Gilead. Now British scientists say SRA737 has the potential to treat several tumor types as part of a combination with another protein blocker.